Page 169 - 2019_03-Haematologica-web

Maraviroc inhibits cHL crosstalk and xenograft growth
erability of a maraviroc-containing regimen in routine clinical practice. Curr HIV Res. 2010;8(6):482-486.
30. Velasco-Velazquez M, Jiao X, De La Fuente M, et al. CCR5 antagonist blocks metasta- sis of basal breast cancer cells. Cancer Res. 2012;72(15):3839-3850.
31. Halvorsen EC, Hamilton MJ, Young A, et al. Maraviroc decreases CCL8-mediated migration of CCR5(+) regulatory T cells and reduces metastatic tumor growth in the lungs. Oncoimmunology. 2016; 5(6):e1150398.
32. Tanabe Y, Sasaki S, Mukaida N, Baba T. Blockade of the chemokine receptor, CCR5, reduces the growth of orthotopical- ly injected colon cancer cells via limiting cancer-associated fibroblast accumulation. Oncotarget. 2016;7(30):48335-48345.
33. Weiswald LB, Bellet D, Dangles-Marie V. Spherical cancer models in tumor biology. Neoplasia. 2015;17(1):1-15.
34. Mencarelli A, Graziosi L, Renga B, et al. CCR5 antagonism by maraviroc reduces the potential for gastric cancer cell dissemi- nation. Transl Oncol. 2013;6(6):784-793.
35. Lejmi E, Perriraz N, Clement S, et al. Inflammatory chemokines MIP-1delta and MIP-3alpha are involved in the migration of multipotent mesenchymal stromal cells induced by hepatoma cells. Stem Cells Dev. 2015;24(10):1223-1235.
36. Poggi A, Zocchi MR. Stress immunity in lymphomas: mesenchymal cells as a target of therapy. Front Biosci (Landmark Ed). 2014;19:281-290.
37. Zocchi MR, Catellani S, Canevali P, et al. High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas. Blood. 2012;119(6):1479-1489.
38. Barros MH, Segges P, Vera-Lozada G, Hassan R, Niedobitek G. Macrophage polar- ization reflects T cell composition of tumor
microenvironment in pediatric classical Hodgkin lymphoma and has impact on sur- vival. PLoS One. 2015; 10(5):e0124531.
39.Dorsam B, Bosl T, Reiners KS, et al. Hodgkin lymphoma-derived extracellular vesicles change the secretome of fibroblasts toward a CAF phenotype. Front Immunol. 2018;9:1358.
40. Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncol- ogy. Nat RevClin Oncol. 2017;14(7):399- 416.
41. Carey CD, Gusenleitner D, Lipschitz M, et al. Topological analysis reveals a PD-L1- associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lym- phoma. Blood. 2017;130(22):2420-2430.
42. Jiao X, Velasco-Velazquez MA, Wang M, et al. CCR5 governs DNA damage and breast cancer stem cell expansion. Cancer Res. 2018;78(7):1657-1671.
haematologica | 2019; 104(3)
575